<DOC>
	<DOCNO>NCT00004762</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate effect cladribine ( 2-chlorodeoxyadenosine ; 2-CdA ) biochemical , radiologic , histologic parameter patient early stage primary sclerosing cholangitis .</brief_summary>
	<brief_title>Phase II Pilot Study Cladribine ( 2-Chlorodeoxyadenosine ; 2-CdA ) Early Stage Primary Sclerosing Cholangitis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients treat subcutaneous injection cladribine ( 2-chlorodeoxyadenosine ; 2-CdA ) 5 consecutive day every month 3 month .</detailed_description>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Stage IIII primary sclerosing cholangitis Radiologically pathologically document No concomitant liver disease , e.g . : Viral hepatitis Autoimmune hepatitis Primary biliary cirrhosis Cirrhosis Portal hypertension associate complication Jaundice cause dominant stricture Prior/Concurrent Therapy No concurrent immunosuppressives Patient Characteristics Hematopoietic : Absolute neutrophil count least 2500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Other : No active infection No fistula abscess No active inflammatory bowel disease Quiescent disease allow , include : Chronic ulcerative colitis Crohn 's disease No significant immunologic disorder No active malignancy No active alcohol drug abuse No pregnant nursing woman Effective contraception require fertile patient Endoscopic retrograde cholangiopancreatography within 36 month prior registration Liver biopsy within 12 month prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>gastrointestinal disorder</keyword>
	<keyword>primary sclerosing cholangitis</keyword>
	<keyword>rare disease</keyword>
</DOC>